Drug intelligence / Profile preview

chlorambucil + prednisolone

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Chlorambucil + prednisolone is a combination therapy containing the alkylating agent chlorambucil and the corticosteroid prednisolone. Chlorambucil is an immunosuppressant and antineoplastic drug that forms covalent bonds with nucleic acids, disrupting DNA strands and suppressing antibody production. It is most effective during the resting phase of the cell cycle and is cell cycle non-specific. Prednisolone is a steroid hormone that works synergistically with chlorambucil. The combination is more efficacious than single drugs because different drugs kill cancer cells in different ways.

Other names: chlorambucil-prednisonechlorambucil-prednisolone

Targets

GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on chlorambucil + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorambucil + prednisolone.

Explore the full profile